Platform Comparison
How Ambrosia Compares
1,600+ real biopharma deals. 14 calculation engines. 12 therapeutic areas. See how Ambrosia stacks up against the legacy platforms.
Ambrosia vs EvaluatePharma
Consensus forecasts vs deal-specific benchmarking
EvaluatePharma excels at consensus revenue forecasts and pipeline analytics. Ambrosia focuses on deal-specific mechanics — upfronts, milestones, royalties, and real-time comparable deal intelligence.
EvaluatePharma strengths
Ambrosia edge
Ambrosia vs S&P Capital IQ
Broad financial data vs deal-specific depth
Capital IQ covers M&A, equity, and credit data across all industries. Ambrosia goes deep on biopharma licensing deal terms — the economics that drive BD decisions.
S&P Capital IQ strengths
Ambrosia edge
Ambrosia vs Clarivate Cortellis
Pipeline intelligence vs deal economics
Cortellis provides deep pipeline and regulatory intelligence. Ambrosia delivers the deal economics layer — benchmarking, valuation, and competitive dynamics that Cortellis does not cover.
Clarivate Cortellis strengths
Ambrosia edge
Ready to see the difference? Try Ambrosia with your own deal parameters.